GB Sciences, Inc. is a research-driven biotechnology company focused on the development and commercialization of cannabinoid-based products for medical, wellness and consumer markets. Headquartered in Orlando, Florida, GB Sciences leverages in-house laboratories and state cultivation facilities to pioneer novel formulations derived from cannabis and hemp plants. The company’s mission centers on advancing scientific understanding of cannabinoids while delivering safe, high-quality products to patients and adult-use consumers.
Central to GB Sciences’ operations are its integrated research and development, cultivation, extraction and formulation capabilities. The company’s product pipeline spans tinctures, oils, topical applications and inhalable formulations, each designed to address a range of health conditions such as chronic pain, neurodegenerative disorders and immune-related ailments. GB Sciences also is pursuing pharmaceutical-grade cannabinoid molecules, engaging in preclinical studies and formulation work aimed at creating regulated drug products.
While primarily serving the U.S. market—particularly Florida, where it holds state cultivation and processing licenses—GB Sciences has forged relationships to expand its footprint internationally. Collaborations in The Bahamas support tropical cultivation and genetic research, and the company is exploring partnerships in Europe and Latin America to broaden distribution of its consumer brands. Through strategic alliances with academic institutions, GB Sciences enhances its research capabilities and accelerates product development.
Founded in 2011 and rebranded in 2014 to emphasize its focus on cannabinoids, GB Sciences is guided by an experienced leadership team and scientific advisory board. Management brings expertise in biotechnology, pharmacology and regulatory affairs, steering the company’s growth from early-stage research into commercial operations. This blend of scientific rigor and entrepreneurial drive underpins GB Sciences’ goal of becoming a leading innovator in the emerging cannabinoid industry.
AI Generated. May Contain Errors.
Free GBLX Stock Alerts